Navigation Links
IsoPlexis Collaboration Offers Breakthrough Insights into Detecting and Predicting Patient Response to T-Cell Therapy
Date:4/3/2017

WASHINGTON, April 3, 2017 /PRNewswire-USNewswire/ -- Data captured by IsoCode, IsoPlexis Corporation's (IsoPlexis) single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.

These findings, the result of a collaboration between IsoPlexis and Kite, were presented today at the American Association for Cancer Research's Annual Meeting. 

"IsoPlexis was excited to collaborate with Kite on this groundbreaking research," said IsoPlexis Chief Executive Officer Sean Mackay. "Using our single-cell precision engineering platform, leading oncology and immunotherapy researchers and clinicians were able to collect these data, which demonstrate a potential to optimize therapies and therapeutic interventions for patients, and ultimately drive better patient outcomes in this rapidly growing field."

Researchers used IsoCode, previously referred to as SCBC in the literature, to analyze CAR-T cell therapy products for 20 patients with non-Hodgkin lymphoma. Using IsoCode, researchers captured data to determine the PSI, or cellular functional profile and strength, of each product. This PSI metric was able to predict complete or partial patient response to the product, with statistical significance.

Adrian Bot, M.D., Kite's Vice President, Translational Medicine, said, "Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer, leading to new ways to characterize and optimize T-cell products. These insights were made possible by using the IsoPlexis technology."

Arnold Levine, PhD, Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton and an IsoPlexis Scientific Advisory Board Member, said, "The quality and precision of these data captured by IsoPlexis technology is exceptional and permits for the first time real precision medicine and early intervention in T-cell production." He added, "IsoPlexis technology can help researchers improve the development and targeting of treatments, enabling truly precise medicine and better patient outcomes."

The abstract is available online: http://www.abstractsonline.com/pp8/#!/4292/presentation/1309

A webcast of the presentation will be posted on the AACR website on April 26.

ABOUT ISOPLEXIS:

IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Caltech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isoplexis-collaboration-offers-breakthrough-insights-into-detecting-and-predicting-patient-response-to-t-cell-therapy-300432888.html


'/>"/>
SOURCE IsoPlexis Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Personalized Medicine - Scientific and Commercial Aspects - 318 Companies Profiled with 575 Collaborations - Research and Markets
2. STMicroelectronics and Valencell Announce Collaboration on Highly Accurate and Powerful Biometric Sensor Platform for Wearables and IoT
3. FIND And Cepheid Announce A Strategic Collaboration To Advance Point-Of-Care TB Diagnosis
4. NXT-ID, Inc. Announces Collaboration with Celebrity Joey Fatone
5. Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health
6. Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc
7. Collaboration drives achievement in protein structure research
8. Calico enters into exclusive collaboration with 2M to develop UTSW technology
9. Research institutions announce collaboration for sharing, standardizing neuroscience data
10. Urban Water Management Workshop stresses more collaboration and innovation
11. ASHG and the Jackson Laboratory launch educational collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , Aug. 23, 2017  The general public,s help is being ... microbiome—the bacteria that live in and on the human body –and are ... The Microbiome ... the human microbiome, starting with the gut. The project's goal is to ... Photo credit: IBM ...
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks Associates ... will speak at the TMA 2017 Annual Meeting , October 11 ... in the residential home security market and how smart safety and security ... Parks Associates: ... "The residential security ...
Breaking Biology Technology: